Vanguard Capital Management
RVMD icon

Vanguard Capital Management’s Revolution Medicines RVMD Stock Holding History

Vanguard Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7B Buy
9,088,661
+726,377
+9% +$106M 0.04% 365
2026
Q1 		$813M Buy
+8,362,284
New +$844M 0.02% 530

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's RVMD Position: Q2 2026 in Review

Vanguard Capital Management increased its Revolution Medicines (RVMD) stake by 8.7% in Q2 2026, buying an estimated $106M and bringing the position to 9,088,661 shares worth $1.7B. The position accounts for 0.04% of the portfolio, ranked #365.

Vanguard Capital Management first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 637 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Vanguard Capital Management held 9,088,661 shares of Revolution Medicines worth $1.7B as of Q2 2026.
  • Vanguard Capital Management bought 726,377 Revolution Medicines shares in Q2 2026, an estimated $106M.
  • Revolution Medicines made up 0.04% of Vanguard Capital Management's portfolio in Q2 2026, its #365 holding.
  • Vanguard Capital Management first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 637 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.